Hormone replacement therapy with dydrogesterone and 17β-oestradiol: Effects on serum lipoproteins and glucose tolerance during 24 month follow up

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue 3, 1997, Pages 298-304

  Crook, David ^a   Godsland, Ian F ^a   Hull, Jane ^b   Stevenson, John C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b Napolitano and Prof David)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGESTONE ACETOFENIDE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS; BLOOD GLUCOSE; CHOLESTEROL; DYDROGESTERONE; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LIPIDS; LIPOPROTEINS; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0031041621     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb11457.x     Document Type: Article

References (26)

1. Persson IR, Adami HO, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. BMJ 1989; 298: 147–151.
2. Whitehead MI, Hillard T, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75: 59–76.
3. Hillard TC, Bourne TH, Whitehead MI, Crayford TB, Collins WP, Campbell S. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril 1992; 58: 959–963.
4. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–667.
5. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199–208.
6. Reerink EH, Schölar HFL, Westerof P et al. A new class of hormonally active steroids. Nature 1960; 186: 168–169.
7. Aydar CK, Greenblatt RB. 6-dehydro-retroprogesterone (Duphaston): An interesting progesterone-like compound. Int J Fertil 1964; 9: 585–595.
8. Siddle NC, Fraser D, Whitehead MI et al. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990; 97: 1101–1107.
9. Burch DJ, Spowart KJM, Jesinger DK, Randall S, Smith S. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17b oestradiol. BrJ Obstet Gynaecol 1995; 102: 243–248.
10. Siddle NC, Jesinger DK, Whitehead MI, Turner P, Lewis B, Prescott P. Effects on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990; 97: 1093–1100.
11. van der Mooren MJ, Demacker PNM, Thomas CMG, Rolland R. Beneficial effects on serum lipoproteins by 17-β-oestradiol-dydrogesterone therapy in postmenopausal women—a prospective study. Eur J Obstet Gynaecol Reprod Biol 1992; 47: 153–160.
12. Voetberg GA, Netelenbos, JC, Kenemans P, Peters-Muller ERA, van de Weijer PHM. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: Effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994; 79: 1465–1469.
13. Warnick G, Albers J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978; 19: 65–76.
14. Gidez L, Miller G, Burstein M, Slagle S, Eder H. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982; 23: 1206–1223.
15. Mount J, Kearney E, Rosseneu M, Slavin B. Immunoturbidimetric assays for serum apolipoproteins Al and B using Cobas Bio centrifugal analyser. J Clin Pathol 1988; 41: 471–74.
16. Crook D, Godsland IF, Worthington M, Felton C, Proudler AJ, Stevenson JC. A comparative metabolic study of two low estrogen dose oral contraceptives containing gestodene or desogestrel progestins. Am J Obstet Gynecol 1993; 169: 1183–1189.
17. Godsland IF, Crook D, Simpson R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. NEngl J Med 1990; 323: 1375–1381.
18. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement therapy on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–1203.
19. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950–955.
20. Seed M, Crook D. Hormone replacement therapies, cardiovascular disease and plasma lipoproteins. Curr Op Lipidology 1994; 5: 48–58.
21. van der Mooren MJ, de Graaf J, Demacker PNM, de Haan AFJ, Rolland R. Changes in the low density lipoprotein profile during 17β- estradiol-dydrogesterone therapy in postmenopausal women. Metabolism 1994; 43: 799–802.
22. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics prevalence study. Am J Epidemiol 1990; 131: 32–47.
23. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow up Study. Circulation 1987; 75: 1102–1109.
24. Silvennan DI, Ginsberg GS, Pasternak RC. High-density lipoprotein subtractions. Am J Med 1993; 94: 636–645.
25. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992; 74: 1396–1400.
26. Stout RW. Insulin resistance, hyperinsulinemia, dyslipidemia and atherosclerosis. In: Moller DE, editor. Insulin Resistance. New York : Wiley, 1993: 354–384.